Deliver Your News to the World

Mammoth Biosciences Awarded Key Patents for Novel CRISPR Diagnostics Methods

The patents, issued in collaboration with UC Berkeley, mark a pivotal turning point in the ongoing CRISPR IP battle


Mammoth Biosciences, the company behind the world’s first CRISPR-based disease detection platform, today announced that the United States Patent and Trademark Office (USPTO) has granted the earliest priority patents for CRISPR collateral cleavage diagnostic systems. The US Patents (No 10,253,365; No 10,337,051) cover comprehensive techniques that enable Mammoth to now offer DNA and RNA detection and are the first-of-their-kind granted in CRISPR diagnostics. The recognition solidifies Mammoth’s leadership in this up-and-coming space. 

The rights to CRISPR technology have been hotly contested, most notably between the Broad Institute and the University of California, Berkeley. Now, these newly issued patents uniquely position Mammoth to commercialize applications on Mammoth’s exciting new CRISPR-enabled detection platform, strengthening their leadership in CRISPR diagnostics.

Similar to how Google searches and finds information on the web, Mammoth’s platform leverages the power of CRISPR to search and find DNA or RNA that are indicative of disease. The company aims to leverage this technology to democratize disease detection, with a vision to develop easy, affordable, and effective tests that can be used in a variety of formats from central labs and point-of-care settings such as hospitals and clinics to even enabling the use of these types of diagnostics at home. Beyond healthcare, Mammoth is developing tests and partnering with others to explore applications in a wide range of industries, such as agriculture, oil and gas, and forensics, and these patents are major wins for the company’s novel detection platform.  

“We launched Mammoth with the intention of addressing a much needed affordable, scalable, and high quality platform for diagnostics and these patents takes us one step further in achieving that goal,” explained Trevor Martin, co-founder and CEO of Mammoth Biosciences. “These patents aid us in accelerating the development of our commercial product and open new doors for partners to build upon our CRISPR-enabled platform for applications in diagnostics and beyond. We were very excited to see how quickly these patents issued, which demonstrates their importance and fundamental contributions to the field.”

Earlier this year, Mammoth announced the exclusive licensing of the novel Cas14 from UC Berkeley for use in diagnostic and therapeutic applications. This new patent further bolsters the company’s IP portfolio and advances its goals toward commercialization. 

For more information visit

About Mammoth Biosciences:

Mammoth Biosciences is a biotech company that has developed the world’s first and only CRISPR-based detection platform capable of sensing any biomarker or disease with DNA/RNA. The company’s co-founders include CRISPR pioneer Jennifer Doudna, Berkeley PhDs Janice Chen and Lucas Harrington, and Stanford PhD Trevor Martin. Mammoth is on a mission to leverage the power of CRISPR to democratize disease detection by bringing accurate and affordable testing out of the laboratory and into the point-of-care. The company has raised nearly $25 million in funding led by top investors including Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos, along with Tim Cook, Brook Byers, Bob Nelsen, and Jeff Huber. 


 Mammoth Biosciences
 Jennifer Doudna

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.